AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer

I. V. Subramanian; S. Devineni; Rahel G Ghebre; G. Ghosh; H. P. Joshi; Yawu Jing; A. M. Truskinovsky; Sundaram Ramakrishnan

doi:10.1038/gt.2010.118

AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer

I. V. Subramanian, S. Devineni, Rahel G Ghebre, G. Ghosh, H. P. Joshi, Yawu Jing, A. M. Truskinovsky, Sundaram Ramakrishnan

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Endostatin potentiates the antimitotic effects of paclitaxel (taxol) on endothelial cells (ECs). P125A-endostatin and taxol-treated ECs showed multipolar spindles and nuclear lobulation, leading to mitotic catastrophe and cell death. Induction of nuclear abnormalities was found to be dependent on Β-catenin levels as wnt-mediated overexpression of Β-catenin reversed the changes in nuclear morphology. These results prompted us to investigate whether antiangiogenic gene therapy and paclitaxel chemotherapy can synergistically inhibit angiogenesis and tumor growth. We first determined the effect of combination treatment in a transgenic mouse model of breast cancer. Intramuscular injection of recombinant adeno-associated virus type-2 virus induced sustained expression of P125A-endostatin. In vivo studies showed that combination therapy inhibited mammary cancer growth, delayed the onset of multifocal mammary adenocarcinomas, decreased tumor angiogenesis and increased survival in treated mice. In a second model, female athymic mice were orthotopically transplanted with a metastatic human breast cancer cell line. Antiangiogenic gene therapy in combination with paclitaxel inhibited tumor angiogenesis and lung/lymph-node metastasis in this model. These studies demonstrate cooperation between endostatin gene therapy and chemotherapy to inhibit tumor initiation, growth and metastasis.

Original language	English (US)
Pages (from-to)	145-154
Number of pages	10
Journal	Gene therapy
Volume	18
Issue number	2
DOIs	https://doi.org/10.1038/gt.2010.118
State	Published - Feb 2011

Bibliographical note

Funding Information:
This work was supported, in part, by grants from the NIH CA-114340 and Shirley Ann Sparboe Endowment for Women’s Cancer Research. We acknowledge Mr G Sedgwick and Mr J Oja of Biomedical Imaging and Processing Laboratory for helping with the confocal images. We also thank Ms Julia Nguyen for her technical support.

Keywords

antiangiogenesis
breast cancer
chemotherapy
orthotopic models
prevention model

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/gt.2010.118

Find It

Find It at U of M Libraries

Cite this

@article{6a815d6bfb1c4f13b6a2d0745a240113,

title = "AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer",

abstract = "Endostatin potentiates the antimitotic effects of paclitaxel (taxol) on endothelial cells (ECs). P125A-endostatin and taxol-treated ECs showed multipolar spindles and nuclear lobulation, leading to mitotic catastrophe and cell death. Induction of nuclear abnormalities was found to be dependent on Β-catenin levels as wnt-mediated overexpression of Β-catenin reversed the changes in nuclear morphology. These results prompted us to investigate whether antiangiogenic gene therapy and paclitaxel chemotherapy can synergistically inhibit angiogenesis and tumor growth. We first determined the effect of combination treatment in a transgenic mouse model of breast cancer. Intramuscular injection of recombinant adeno-associated virus type-2 virus induced sustained expression of P125A-endostatin. In vivo studies showed that combination therapy inhibited mammary cancer growth, delayed the onset of multifocal mammary adenocarcinomas, decreased tumor angiogenesis and increased survival in treated mice. In a second model, female athymic mice were orthotopically transplanted with a metastatic human breast cancer cell line. Antiangiogenic gene therapy in combination with paclitaxel inhibited tumor angiogenesis and lung/lymph-node metastasis in this model. These studies demonstrate cooperation between endostatin gene therapy and chemotherapy to inhibit tumor initiation, growth and metastasis.",

keywords = "antiangiogenesis, breast cancer, chemotherapy, orthotopic models, prevention model",

author = "Subramanian, {I. V.} and S. Devineni and Ghebre, {Rahel G} and G. Ghosh and Joshi, {H. P.} and Yawu Jing and Truskinovsky, {A. M.} and Sundaram Ramakrishnan",

note = "Funding Information: This work was supported, in part, by grants from the NIH CA-114340 and Shirley Ann Sparboe Endowment for Women{\textquoteright}s Cancer Research. We acknowledge Mr G Sedgwick and Mr J Oja of Biomedical Imaging and Processing Laboratory for helping with the confocal images. We also thank Ms Julia Nguyen for her technical support.",

year = "2011",

month = feb,

doi = "10.1038/gt.2010.118",

language = "English (US)",

volume = "18",

pages = "145--154",

journal = "Gene therapy",

issn = "0969-7128",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer

AU - Subramanian, I. V.

AU - Devineni, S.

AU - Ghebre, Rahel G

AU - Ghosh, G.

AU - Joshi, H. P.

AU - Jing, Yawu

AU - Truskinovsky, A. M.

AU - Ramakrishnan, Sundaram

N1 - Funding Information: This work was supported, in part, by grants from the NIH CA-114340 and Shirley Ann Sparboe Endowment for Women’s Cancer Research. We acknowledge Mr G Sedgwick and Mr J Oja of Biomedical Imaging and Processing Laboratory for helping with the confocal images. We also thank Ms Julia Nguyen for her technical support.

PY - 2011/2

Y1 - 2011/2

N2 - Endostatin potentiates the antimitotic effects of paclitaxel (taxol) on endothelial cells (ECs). P125A-endostatin and taxol-treated ECs showed multipolar spindles and nuclear lobulation, leading to mitotic catastrophe and cell death. Induction of nuclear abnormalities was found to be dependent on Β-catenin levels as wnt-mediated overexpression of Β-catenin reversed the changes in nuclear morphology. These results prompted us to investigate whether antiangiogenic gene therapy and paclitaxel chemotherapy can synergistically inhibit angiogenesis and tumor growth. We first determined the effect of combination treatment in a transgenic mouse model of breast cancer. Intramuscular injection of recombinant adeno-associated virus type-2 virus induced sustained expression of P125A-endostatin. In vivo studies showed that combination therapy inhibited mammary cancer growth, delayed the onset of multifocal mammary adenocarcinomas, decreased tumor angiogenesis and increased survival in treated mice. In a second model, female athymic mice were orthotopically transplanted with a metastatic human breast cancer cell line. Antiangiogenic gene therapy in combination with paclitaxel inhibited tumor angiogenesis and lung/lymph-node metastasis in this model. These studies demonstrate cooperation between endostatin gene therapy and chemotherapy to inhibit tumor initiation, growth and metastasis.

AB - Endostatin potentiates the antimitotic effects of paclitaxel (taxol) on endothelial cells (ECs). P125A-endostatin and taxol-treated ECs showed multipolar spindles and nuclear lobulation, leading to mitotic catastrophe and cell death. Induction of nuclear abnormalities was found to be dependent on Β-catenin levels as wnt-mediated overexpression of Β-catenin reversed the changes in nuclear morphology. These results prompted us to investigate whether antiangiogenic gene therapy and paclitaxel chemotherapy can synergistically inhibit angiogenesis and tumor growth. We first determined the effect of combination treatment in a transgenic mouse model of breast cancer. Intramuscular injection of recombinant adeno-associated virus type-2 virus induced sustained expression of P125A-endostatin. In vivo studies showed that combination therapy inhibited mammary cancer growth, delayed the onset of multifocal mammary adenocarcinomas, decreased tumor angiogenesis and increased survival in treated mice. In a second model, female athymic mice were orthotopically transplanted with a metastatic human breast cancer cell line. Antiangiogenic gene therapy in combination with paclitaxel inhibited tumor angiogenesis and lung/lymph-node metastasis in this model. These studies demonstrate cooperation between endostatin gene therapy and chemotherapy to inhibit tumor initiation, growth and metastasis.

KW - antiangiogenesis

KW - breast cancer

KW - chemotherapy

KW - orthotopic models

KW - prevention model

UR - http://www.scopus.com/inward/record.url?scp=79951515453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951515453&partnerID=8YFLogxK

U2 - 10.1038/gt.2010.118

DO - 10.1038/gt.2010.118

M3 - Article

C2 - 20844568

AN - SCOPUS:79951515453

SN - 0969-7128

VL - 18

SP - 145

EP - 154

JO - Gene therapy

JF - Gene therapy

IS - 2

ER -

AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this